Cantor starts Organogenesis at overweight, cites differentiated portfolio (NASDAQ:ORGO)

Bull market. Golden bull in front of laptop with stock charts. Financial investment and trading concept.


Cantor Fitzgerald has initiated coverage of Organogenesis (NASDAQ:ORGO) with an overweight rating, citing attractive valuation and the company’s highly differentiated technology portfolio.

Cantor said it holds a favorable view of the estimated $24B advanced wound care and surgical/sports medicine markets. It sees

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *